BioSante Pharmaceuticals, Inc.
BioSante Pharmaceuticals, Inc. Discusses LibiGel(R) and its Cancer Vaccines in Fireside Chat with Research Analyst
Published in Vaccine Weekly, April 14th, 2010
Stephen M. Simes, president and CEO of BioSante presented an in-depth view of the Company's strategy, development pipeline and clinical milestones, during an interview by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC (NASDAQ: RODM). The topics discussed included an overview of BioSante and specifically a thorough discussion of LibiGel® (testosterone gel), in development for the treatment of female sexual dysfunction, as well as BioSante's portfolio of GVAX cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2010-04-14)
More Articles from Vaccine Weekly
- Biotechnology and Biological Sciences Research Council
Songbird genome to aid understanding of learning, memory and more - Biotechnology Business
Studies conducted at W.A. Valdiviagranda et al on biotechnology business recently published - Helicobacter pylori
Study results from Chongqing Medical University provide new insights into helicobacter pylori - Hepatitis
Research findings from M. Ajelli et al update understanding of hepatitis - HIV/AIDS Vaccine
GeoVax Labs Granted Allowance By FDA to Start Phase 1 Clinical - Human Papillomavirus
Scientists at Aristotle University describe research in human papillomavirus - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
